Yulan Zhou

Emerging frontiers in targeted and immunotherapeutic strategies for marginal zone lymphoma

Marginal zone lymphoma (MZL) comprises a heterogeneous group of indolent B-cell non-Hodgkin lymphomas. Most patients have favorable outcomes, but approximately 20% develop early relapse or progression within 24 months. Advances in molecular profiling have identified recurrent alt...